Up-to-date List of Haemorrhage Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Haemorrhage Medical Research Studies

1 Recruiting RCT of Stent Versus Standard Therapy in Oesophageal Variceal Haemorrhage
Condition: Acute Bleeding Esophageal Varices
Interventions: Device: Self-expanding mesh-metal oesophageal stent (SEMS);   Other: Standard Therapy
Outcome Measures: Failure to Control Bleeding;   Absence of Bleeding at 14 and 42 days;   Participant Survival;   Absence of Stent Migration;   Requirement for Blood products;   Requirement for Analgesia and Sedation whilst Stent in in situ;   Presence of Thoracic Pain or Dysphagia;   Length of Intensive Care Unit and Total Hospital Stay;   Requirement for additional endoscopic therapy or salvage therapy (such as TIPS);   Repeated presentation with variceal bleeding within 6 months
2 Recruiting Bilateral Uterine Compression to Reduce Blood Loss and Prevent Postpartum Haemorrhage After Vaginal Delivery
Condition: Postpartum Haemorrhage
Intervention: Procedure: bilateral uterine compression
Outcome Measures: Blood loss 500 ml or more after enrolment;   Blood loss 1000 ml or more after enrolment;   Use of additional uterotonics or other procedures;   Blood transfusion
3 Recruiting Association Between Haptoglobin Genotype and Brain Swelling
Condition: Intracerebral Hemorrhage
Intervention: Other: Intracerebral Hemorrhage
Outcome Measure: Perihematomal Edema Volume
4 Not yet recruiting Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes During Major Obstetric Haemorrhage
Condition: Postpartum Haemorrhage
Outcome Measures: Early haemostatic predictors of major obstetric Haemorrhage;   Evaluation of ROTEM-based MOH prediction scores as alternative to traditional haemostatic parameters;   Incidence of underlying bleeding disorders in patients with MOH;   Predictive value bleeding score in pregnancy for MOH
5 Recruiting Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
Condition: Postpartum Hemorrhage
Interventions: Drug: carbetocin;   Drug: misopristol;   Drug: oxytocin
Outcome Measures: control of postpartum hemorrhage;   time of control of bleeding, amount of blood loss till control of bleeding, changes in the hemoglobin and hematocrite levels, use of additional uterotonic drugs, necessity for surgical intervention, and the rate of complications.
6 Recruiting PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Conditions: Brain Ischemia;   Intracranial Hemorrhages
Interventions: Drug: Cilostazol;   Drug: Probucol;   Drug: Aspirin;   Drug: placebo of cilostazol;   Drug: placebo of aspirin;   Device: ankle-brachial index (ABI);   Device: intima-medial thickness (IMT);   Device: new asymptomatic brain hemorrhage;   Device: new ischemic lesions on follow-up FLAIR images
Outcome Measures: time to first occurrence of cerebral hemorrhage;   time to first occurrence of cardiovascular events;   Time to the first occurrence of stroke;   Time to the first occurrence of ischemic stroke;   Time to the first occurrence of myocardial infarction;   Time to the first occurrence of other designated vascular events;   time to occurrence of major bleeding complications;   occurrence of new microbleedings or asymptomatic new hemorrhage on GRE image;   new ischemic lesions on FLAIR images;   change of Ankle-Brachial Index;   change of intima-medial thickness;   time to occurrence of any death
7 Not yet recruiting Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
Condition: Postpartum Hemorrhage
Interventions: Procedure: Routine care;   Device: Bakri balloon
Outcome Measures: The % of patients requiring invasive measures for postpartum hemorrhage control.;   The total cost (€) associated with the postpartum hemorrhage management strategy.;   The delay required to stop bleeding post-delivery (min);   The delay required to stop bleeding post-diagnosis (min);   The percentage of patients still bleeding 30 minutes after sulprostone injection;   Blood loss (ml) 30 minutes after diagnosis;   Blood loss (ml) 1 hour after diagnosis;   Blood loss (ml) 2 hours after diagnosis;   Blood loss (ml) 24 hours after diagnosis;   Blood pressure;   Heart rate;   The % of patients requiring blood transfusion.;   The % of patients requiring intravenous iron.;   The quantity of packed red cells, platelet concentrate and fresh frozen plasma consumed;   Fibrinogen (g / l);   Hematocrit (%);   Hemoglobin (g/dl);   Prothrombin (%);   Activated partial thromboplastin time (s);   Length of hospital stay (days);   Length of ICU stay;   Antimullerian hormone level;   Amenorrhea at 3 months? yes/no;   The presence of adhesions detected at hysteroscopy;   pain will be assessed in both arms via a visual analog scale, duration, location, and use of analgesics;   temperature (°C);   FSFI questionnaire (Female Sexual Function Index);   Doppler ultrasound: intra-uterine pressure;   Doppler ultrasound: thickness of the uterine wall;   Doppler ultrasound: inversed diastolic flow;   Doppler ultrasound: intraluminal pressure;   Doppler ultrasound: uterine artery perfusion pressure;   Doppler ultrasound: uterine artery pulsatility index;   IES-R scale (symptoms of post-traumatic stress)
8 Recruiting Observational Study in Preterm Infants With Intracranial Hemorrhage
Conditions: Intracranial Hemorrhage;   Intraventricular Hemorrhage;   Cerebral Hypoxia
Outcome Measures: Progression of cerebral oxygenation;   Progression of cerebral perfusion and function
9 Unknown  Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage
Condition: Postpartum Hemorrhage
Intervention: Drug: oxygen
Outcome Measures: The primary outcome was the amount of blood loss in the third and fourth stages of labor.;   incidences of Postpartum Haemorrhage (PPH) (≥500 ml)
10 Recruiting Prediction of Major Bleeding in ELBW-infants (<1000g) by Sequential Coagulation Monitoring
Conditions: Intraventricular Haemorrhage; Pulmonary Haemorrhage
Intervention: Device: Coaguchek
Outcome Measures: major bleeding;   mortality
11 Recruiting Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage
Conditions: Intraventricular Hemorrhage;   Autoregulation
Interventions: Other: Hypercapnia;   Other: Normocapnia
Outcome Measures: The effect of hypercapnia vs. normocapnia on the development of Grade II-IV intraventricular hemorrhage/periventricular leukomalacia (severe brain injury) and/or death;   The effect of hypercapnia vs. normocapnia on the development of chronic lung disease (requirement of supplemental oxygen at 36 weeks corrected gestational age);   The effect of hypercapnia vs. normocapnia on abnormal results from MRIs;   The effect of hypercapnia vs. normocapnia on the development of pulmonary hemorrhage
12 Recruiting Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment
Conditions: Coronary Occlusion/Thrombosis;   Peptic Ulcer Hemorrhage
Intervention: Other: Screening for risk factors for ulcer bleeding
Outcome Measures: Admission for ulcer bleeding or haemorrhagic gastritis;   Compliance with antithrombotic medicine;   Identification of patients with Benefit of Proton pump inhibitor Prophylaxis;   Gastrointestinal bleeding;   Uncomplicated ulcers;   Death;   Acute coronary syndrome
13 Recruiting The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-ß 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage
Conditions: Subarachnoid Hemorrhage;   Terson Syndrome;   CSF-proteines
Outcome Measures: Intracranial pressure (ICP) in mmH20;   Concentration of CSF-protein phospho-tau;   Concentration of CSF-protein amyloid-ß 40/42;   Delayed cerebral ischemia;   Clinically manifest vasospasm;   Re-bleed;   Surgery for refractory ICP (decompressive hemicraniectomy);   Necessity of CSF-shunt;   Opthalmologic exam
14 Recruiting Cardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients
Conditions: Aneurysmal Subarachnoid Heamorrhage;   Nontraumatic Subarachnoid Haemorrhage
Outcome Measure: Incidence of cardiac failure and the impact of cardiac problems on morbidity
15 Recruiting Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage
Condition: Non Traumatic Primary Intracerebral Hemorrhage
Intervention: Other: Pet AV-45 (Florbetapir F 18) Cerebral Amyloid imaging
Outcome Measures: Pet-AV45 cortical binding;   cerebral microbleeds number and distribution on T2EG MRI sequence;   White Matter Lesions Volume on 3D-FLAIR MRI sequence;   Cortical thickness and hippocampal volume on 3D-T1 MRI sequence;   Neuropsychological performances
16 Recruiting Remote Ischemic Preconditioning in Subarachnoid Hemorrhage
Conditions: Subarachnoid Hemorrhage, Aneurysmal;   Subarachnoid Hemorrhage;   Cerebral Vasospasm;   Intracranial Aneurysm
Intervention: Procedure: Remote ischemic preconditioning
Outcome Measures: Occurrence of neurological events, or vasospasm;   Transcranial Doppler Measurements and metabolic assessment
17 Recruiting Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Conditions: Exudative Macular Degeneration;   Retinal Hemorrhage
Interventions: Drug: Ranibizumab;   Drug: C3F8 Gas;   Drug: tPA
Outcome Measures: Mean ETDRS visual acuity;   Percentage patients 15 letters or greater improvement in ETDRS visual acuity;   Percentage patients 0 letters or greater improvement in ETDRS visual acuity;   Percentage patients 15 letters or greater loss in ETDRS visual acuity;   Mean total area of macular Haemorrhage on colour fundus photography;   Greatest linear dimension of macular Haemorrhage on colour fundus photography;   Presence of subfoveal blood on colour fundus photography
18 Recruiting Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive
Conditions: Abnormal Uterine Bleeding, Unspecified;   Uterine Bleeding Heavy
Interventions: Drug: EE 30mcg/LNG 150mcg;   Drug: Placebo
Outcome Measures: Bleeding Improvement;   Adverse Events
19 Recruiting Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum Hemorrhage
Condition: Postpartum Hemorrhage
Intervention: Drug: Oxytocin
Outcome Measures: Proportion of women with postpartum blood loss equal to or greater than 500 mL;   Mean postpartum blood loss;   Proportion of women with postpartum blood loss equal to or greater than 350 mL;   Proportion of women with postpartum blood loss equal to or greater than 1000 mL;   Mean change in hemoglobin pre-delivery to postpartum;   Time to delivery of placenta;   Administration of additional oxytocin, other uterotonics or other interventions such as blood transfusion or hysterectomy;   Side effects 1 hour postpartum
20 Not yet recruiting Continuous Monitoring of Blood Pressure in Spontaneous Intraparenchimal Cerebral Haemorrhage
Condition: Intraparenchimal Cerebral Haemorrhage
Outcome Measure: evaluation of blood pressure varibility on clinical course in patients with cerebral Haemorrhage

These studies may lead to new treatments and are adding insight into Haemorrhage etiology and treatment.

A major focus of Haemorrhage research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Haemorrhage

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us